Visual acuity time in range: a novel concept to describe consistency in treatment response in diabetic macular oedema.

ABSTRACT:

Objective

To assess 'time in range' as a novel measure of treatment response in diabetic macular oedema (DMO).

Methods

This post hoc analysis of the Protocol T randomised clinical trial included 660 individuals with centre-involved DMO and best-corrected visual acuity (BCVA) letter score ≤78-≥24 (approximate Snellen equivalent 20/32-20/320). Study participants received intravitreal aflibercept 2.0 mg, repackaged (compounded) bevacizumab 1.25 mg, or ranibizumab 0.3 mg given up to every 4 weeks using defined retreatment criteria. Mean time in range was calculated using a BCVA letter score threshold of ≥69 (20/40 or better; minimum driving requirement in many regions), with sensitivity analyses using BCVA thresholds from 100 to 0 (20/10 to 20/800) in 1-letter increments.

Res

SUBMITTER: Kozak I 

PROVIDER: S-EPMC10630493 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature